FDA panel recommends Pfizer COVID booster for seniors, high-risk groups
USA: A panel of The Food and Drug Administration (FDA) advisors has approved a third booster dose of Pfizer-BioNTech's COVID-19 vaccine on an emergency use basis. The approval is meant only for the most vulnerable groups included people aged 65 and older and those at high risk of severe disease. The booster dose would be given 6 months after receiving the second dose.
The nonbinding decision was made by the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (VRBPAC) will.
The final vote was passed unanimously on an 18 to 0 vote. An initial vote on a broader third dose in people aged 16 years and older failed 16 to 2, based on the question of its safety and whether third doses would do much to decrease transmission.
The prophylactic, RNA-based SARS-CoV-2 vaccine BNT162b2 [COMIRNATY(COVID-19 Vaccine, mRNA)], developed by BioNTech SE and Pfizer Inc, received US FDA approval on 23 August 2021 for the prevention of COVID-19 disease in individuals ≥16 years of age.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.